AU2006274752A1 - Antibodies directed against an LDL receptor - Google Patents

Antibodies directed against an LDL receptor Download PDF

Info

Publication number
AU2006274752A1
AU2006274752A1 AU2006274752A AU2006274752A AU2006274752A1 AU 2006274752 A1 AU2006274752 A1 AU 2006274752A1 AU 2006274752 A AU2006274752 A AU 2006274752A AU 2006274752 A AU2006274752 A AU 2006274752A AU 2006274752 A1 AU2006274752 A1 AU 2006274752A1
Authority
AU
Australia
Prior art keywords
seq
antibody
ldl
antibody according
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2006274752A
Other languages
English (en)
Inventor
Christian Behrens
Christine Gaucher
Jamila Najib
Jean-Francois Prost
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LFB Biotechnologies SAS
Original Assignee
LFB Biotechnologies SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LFB Biotechnologies SAS filed Critical LFB Biotechnologies SAS
Publication of AU2006274752A1 publication Critical patent/AU2006274752A1/en
Assigned to LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES reassignment LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES Alteration of Name(s) of Applicant(s) under S113 Assignors: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES GROUPEMENT D'INTERET PUBLIC
Assigned to LFB BIOTECHNOLOGIES reassignment LFB BIOTECHNOLOGIES Request for Assignment Assignors: LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2006274752A 2005-08-03 2006-07-25 Antibodies directed against an LDL receptor Abandoned AU2006274752A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0508281 2005-08-03
FR0508281A FR2889532B1 (fr) 2005-08-03 2005-08-03 Anticorps diriges contre le recepteur du ldl
PCT/FR2006/001807 WO2007014992A2 (fr) 2005-08-03 2006-07-25 Anticorps diriges contre le recepteur du ldl

Publications (1)

Publication Number Publication Date
AU2006274752A1 true AU2006274752A1 (en) 2007-02-08

Family

ID=35883519

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2006274752A Abandoned AU2006274752A1 (en) 2005-08-03 2006-07-25 Antibodies directed against an LDL receptor

Country Status (6)

Country Link
EP (1) EP1937722A2 (fr)
JP (1) JP2009502189A (fr)
AU (1) AU2006274752A1 (fr)
CA (1) CA2618050A1 (fr)
FR (1) FR2889532B1 (fr)
WO (1) WO2007014992A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2937322B1 (fr) 2008-10-22 2013-02-22 Vect Horus Derives peptidiques et leur utilisation comme vecteurs de molecules sous forme de conjugues
FR2959229B1 (fr) 2010-04-21 2013-01-18 Vect Horus Derives peptidiques, leur preparation et leurs utilisations
EP3038657A2 (fr) 2013-08-28 2016-07-06 Bioasis Technologies Inc. Conjugués comportant des régions fc modifiées pour cibler le snc et méthodes pour les utiliser
CA3128035A1 (fr) 2020-08-13 2022-02-13 Bioasis Technologies, Inc. Polytherapies pour l'administration dans l'ensemble de la barriere hemato-encephalique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000279174A (ja) * 1999-03-30 2000-10-10 Bml Inc ヒトｌｄｌレセプターに対するモノクローナル抗体及びこれを用いる家族性高脂血症の判定方法
IL139217A0 (en) * 2000-03-13 2001-11-25 Applied Research Systems Monoclonal antibodies to the human ldl receptor, their production and use
CA2425513A1 (fr) * 2000-10-25 2002-06-20 Vincent Agnello Procede d'inhibition de l'infection au virus de l'hepatite c (vhc) et autres virus de la famille des flaviridae, et a tout autre virus formant dans le sang un complexe avec une lipoproteine de basse densite ou tres basse densite, par empechement de l'entree virale dans une cellule

Also Published As

Publication number Publication date
CA2618050A1 (fr) 2007-02-08
FR2889532A1 (fr) 2007-02-09
JP2009502189A (ja) 2009-01-29
FR2889532B1 (fr) 2007-10-12
EP1937722A2 (fr) 2008-07-02
WO2007014992A3 (fr) 2007-04-19
WO2007014992A2 (fr) 2007-02-08

Similar Documents

Publication Publication Date Title
US20230406941A1 (en) Anti-AXL Antagonistic Antibodies
BR122021020513B1 (pt) Anticorpos humanizados para liv-1 e uso dos mesmos para tratar câncer
JP2018524296A (ja) Ｃｄ１２３抗体及びその複合体
US20090175789A1 (en) Antibody raised against the ldl receptor
KR20180050321A (ko) 분자를 표적화하기 위한 항원 결합 구조체
US20220064309A1 (en) IL-7R-alpha SPECIFIC ANTIBODIES FOR TREATING ACUTE LYMPHOBLASTIC LEUKEMIA
CN114127116A (zh) 针对黏蛋白-16的人源化抗体及其使用方法
US11554177B2 (en) Antibody-drug conjugates targeting human Claudin 18.2
WO2017026497A1 (fr) Anticorps
CN113853388A (zh) 抗-egfrviii抗体及其抗原结合片段
JP2016179978A (ja) Ｃｄ２０に対するモノクローナル抗体
AU2017364473B2 (en) Anti-CD300f antibody and uses thereof
CN1946425B (zh) B细胞疾病的靶
US8975377B2 (en) Cancer treatment using humanized antibodies that bind to EphB4
AU2006274752A1 (en) Antibodies directed against an LDL receptor
EP4273169A1 (fr) Développement et utilisation d'un agent de blocage d'anticorps à fonction améliorée
EP4209512A1 (fr) Développement d'un agent thérapeutique contenant un adaptateur et son utilisation
CN113307871B (zh) 新型抗cd19抗体和cd19-car-t细胞的制备及其应用
NZ615285A (en) Novel modulators and methods of use

Legal Events

Date Code Title Description
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 07 FEB 2007 TO 07 MAR 2008 IN WHICH TO COMPLY WITH SECTION 6(C) HAS BEEN FILED .

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO COMPLY WITH SECTION 6(C) HAS BEEN EXTENDED TO 07 MAR 2008.

PC1 Assignment before grant (sect. 113)

Owner name: LFB BIOTECHNOLOGIES

Free format text: FORMER APPLICANT(S): LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period